Attractively, significantly increasing of NKG2DLs was observed on B-lymphoblastoid cell line (B-LCL) of EBV-PTLD [29], indicating their potential as therapeutic targets for EBV-PTLD treatment by NKG2D CAR-T cells. Here, KLRK1 is linked to post-transplant lymphoproliferative disease.